ARAF and lung cancer: By characterizing the gene–drug sensitivity pair of ARAF p.S214C and sorafenib, this study may help establish ARAF p.S214C mutation as a novel biomarker for predicting sorafenib efficacy, which could implicate a new precision medicine strategy for lung cancer.